LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of “Buy” by Analysts
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have been assigned an average rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year […]
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have been assigned an average rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year […]
